IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage

Journal of Hepatology

Volumn 52, Issue 4, 2010, Pages 550-559

  Tovar, Victoria ^a   Alsinet, Clara ^a   Villanueva, Augusto ^a   Hoshida, Yujin ^b   Chiang, Derek Y ^b   Solé, Manel ^a   Thung, Swan ^c   Moyano, Susana ^a   Toffanin, Sara ^c,d   Mínguez, Beatriz ^c   Cabellos, Laia ^c   Peix, Judit ^a   Schwartz, Myron ^c   Mazzaferro, Vincenzo ^d   Bruix, Jordi ^a   Llovet, Josep M ^a,c,e  

^a Liver Unit   (Spain)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

A12; Hepatocellular carcinoma; IGF signaling; miR 100; Molecular therapy

Indexed keywords

A12 MONOCLONAL ANTIBODY; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MONOCLONAL ANTIBODY; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; CHROMOSOME LOSS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HEPATOCYTES; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; RECEPTOR, IGF TYPE 1; RECEPTOR, IGF TYPE 2; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77949875878     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.01.015     Document Type: Article

References (35)

1. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
2. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
3. Villanueva A., Newell P., Chiang D.Y., Friedman S.L., and Llovet J.M. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27 (2007) 55-76
4. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8 (2008) 915-928
5. Peruzzi F., Prisco M., Dews M., Salomoni P., Grassilli E., Romano G., et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 19 (1999) 7203-7215
6. Lu Y., Zi X., and Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 108 (2004) 334-341
7. Breuhahn K., Longerich T., and Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 25 (2006) 3787-3800
8. Tang S.H., Yang D.H., Huang W., Zhou H.K., Lu X.H., and Ye G. Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population. Clin Cancer Res 12 (2006) 4171-4177
9. De Souza A.T., Hankins G.R., Washington M.K., Orton T.C., and Jirtle R.L. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 11 (1995) 447-449
10. Oka Y., Waterland R.A., Killian J.K., Nolan C.M., Jang H.S., Tohara K., et al. M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan. Hepatology 35 (2002) 1153-1163
11. Hanafusa T., Yumoto Y., Nouso K., Nakatsukasa H., Onishi T., Fujikawa T., et al. Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett 176 (2002) 149-158
12. Kim S.O., Park J.G., and Lee Y.I. Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product. Cancer Res 6 (1996) 3831-3836
13. Burtrum D., Zhu Z., Lu D., Anderson D.M., Prewett M., Pereira D.S., et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63 (2003) 8912-8921
14. Rowinsky E.K., Youssoufian H., Tonra J.R., Solomon P., Burtrum D., and Ludwig D.L. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 13 (2007) 5549s-5555s
15. Higano C.S., Yu E.Y., Whiting S.H., Gordon M.S., LoRusso P., Fox F., et al. A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol 25 Suppl. 18 (2007) 3505 [abstract]
16. Chiang D.Y., Villanueva A., Hoshida Y., Peix J., Newell P., Minguez B., et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68 (2008) 6779-6788
17. Armengol C., Tarafa G., Boix L., Sole M., Queralt R., Costa D., et al. Orthotopic implantation of human hepatocellular carcinoma in mice: analysis of tumor progression and establishment of the BCLC-9 cell line. Clin Cancer Res 10 (2004) 2150-2157
18. Wurmbach E., Chen Y.B., Khitrov G., Zhang W., Roayaie S., Schwartz M., et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 45 (2007) 938-947
19. Nardone G., Romano M., Calabro A., Pedone P.V., de S.I., Persico M., et al. Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hepatology 23 (1996) 1304-1312
20. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102 (2005) 15545-15550
21. Mi S., Lu J., Sun M., Li Z., Zhang H., Neilly M.B., et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci USA 104 (2007) 19971-19976
22. Lee H.C., Tian B., Sedivy J.M., Wands J.R., and Kim M. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology 131 (2006) 1208-1217
23. Rubini M., D'Ambrosio C., Carturan S., Yumet G., Catalano E., Shan S., et al. Characterization of an antibody that can detect an activated IGF-I receptor in human cancers. Exp Cell Res 251 (1999) 22-32
24. Tusher V.G., Tibshirani R., and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98 (2001) 5116-5121
25. Villanueva A., Chiang D.Y., Newell P., Peix J., Thung S., Alsinet C., et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135 (2008) 1972-1983
26. Nussbaum T., Samarin J., Ehemann V., Bissinger M., Ryschich E., Khamidjanov A., et al. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology 48 (2008) 146-156
27. Mazziotti G., Sorvillo F., Morisco F., Carbone A., Rotondi M., Stornaiuolo G., et al. Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer 95 (2002) 2539-2545
28. Nam E.J., Yoon H., Kim S.W., Kim H., Kim Y.T., Kim J.H., et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14 (2008) 2690-2695
29. Wong T.S., Liu X.B., Wong B.Y., Ng R.W., Yuen A.P., and Wei W.I. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 14 (2008) 2588-2592
30. Llovet J.M., Di Bisceglie A.M., Bruix J., Kramer B.S., Lencioni R., Zhu A.X., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100 (2008) 698-711
31. Yeh J., Litz J., Hauck P., Ludwig D.L., and Krystal G.W. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt. Lung Cancer 60 (2008) 166-174
32. Goetsch L., Gonzalez A., Leger O., Beck A., Pauwels P.J., Haeuw J.F., et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113 (2005) 316-328
33. Wang Y., Hailey J., Williams D., Wang Y., Lipari P., Malkowski M., et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 4 (2005) 1214-1221
34. Wu K.D., Zhou L., Burtrum D., Ludwig D.L., and Moore M.A. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 56 (2007) 343-357
35. Desbois-Mouthon C., Cacheux W., Blivet-Van Eggelpoel M.J., Barbu V., Fartoux L., Poupon R., et al. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer 119 (2006) 2557-2566